Learn how age, TP53 risk, and lifestyle shape choosing fixed-duration vs continuous CLL therapy, with shared decision tips from Dr Lamanna. While results from the CLL17 trial (NCT04608318) suggest ...
Zacks Investment Research on MSN
Can MRK's ongoing M&A push aid long-term growth ahead of Keytruda LOE?
Merck MRK has been actively pursuing mergers and acquisitions (M&A) to strengthen its pipeline and sustain long-term growth, ...
Dr. Gabriel Mannis from Stanford University and Dr. Gail Roboz from Weill Cornell Medicine discussed the evolving treatment ...
Ascentage Pharma Group International ( AAPG) Q4 2025 Earnings Call March 26, 2026 8:00 AM EDT Good day, everyone, and welcome to Ascentage Pharma's 2025 Annual Results Earnings Call. [Operator ...
Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are ...
Here, doctors share the number-one sign of leukemia in adults over 50, plus other key symptoms like night sweats, weight loss ...
Zacks Investment Research on MSN
Merck to boost oncology pipeline with $6.7B Terns buyout, stock up
Merck MRK announced that it has entered into a definitive agreement to acquire California-based cancer biotech, Terns ...
In a market note, Mizuho raised its price target for Enliven Therapeutics Inc. (NASDAQ:ELVN) to $45 from $41 previously, ...
Merck & Co. has agreed to acquire Terns Pharmaceuticals for approximately $6.7 billion, in a deal designed to bolster the ...
7d
Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires
Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results